A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

摘要

Metastatic prostate cancer, which presents as either (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their disease. Over the past several years, several landmark randomized clinical trials have led to the use of docetaxel, a taxane chemotherapy administered intravenously every 3 weeks for 6 cycles, or abiraterone, an orally administered inhibitor of CYP17A1 given together with a low-dose glucocorticoid, in combination with ADT as standard of care among men with metastatic castration-sensitive prostate cancer (mCSPC) ( - ). The median overall survival with these therapies is upwards of 53 months, depending on the disease stage, extent, and burden of the study population.